Alpha Teknova (NASDAQ:TKNO) & Oruka Therapeutics (NASDAQ:ORKA) Head-To-Head Survey

Oruka Therapeutics (NASDAQ:ORKA) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Valuation and Earnings

This table compares Oruka Therapeutics and Alpha Teknova”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$5.34 million	($6.26)	-1.83
Alpha Teknova	$36.68 million	12.22	-$36.78 million	($0.74)	-11.36

Oruka Therapeutics has higher earnings, but lower revenue than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Oruka Therapeutics and Alpha Teknova, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	7	2	3.22
Alpha Teknova	0	1	2	0	2.67

Oruka Therapeutics currently has a consensus price target of $39.86, suggesting a potential upside of 248.10%. Alpha Teknova has a consensus price target of $8.50, suggesting a potential upside of 1.07%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Oruka Therapeutics is more favorable than Alpha Teknova.

Insider & Institutional Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 22.7% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 15.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Oruka Therapeutics and Alpha Teknova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-24.96%	-21.22%
Alpha Teknova	-87.17%	-35.30%	-24.52%

Risk & Volatility

Oruka Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.

Summary

Oruka Therapeutics beats Alpha Teknova on 12 of the 14 factors compared between the two stocks.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

About Alpha Teknova

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.